Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1200020150390040342
Diabetes & Metabolism Journal
2015 Volume.39 No. 4 p.342 ~ p.347
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
Yagi Shusuke

Aihara Ken-ichi
Akaike Masashi
Fukuda Daiju
Salim Hotimah Masdan
Ishida Masayoshi
Matsuura Tomomi
Ise Takayuki
Yamaguchi Koji
Iwase Takashi
Yamada Hirotsugu
Soeki Takeshi
Wakatsuki Tetsuzo
Shimabukuro Michio
Matsumoto Toshio
Sata Masataka
Abstract
Background: Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment.

Methods: A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3¡¾35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.

Results: After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167¡¾63 to 151¡¾49 mg/dL (P<0.01), and from 7.5%¡¾1.3% to 6.9%¡¾0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.

Conclusion: Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment.
KEYWORD
Coronary artery disease, Diabetes mellitus, Dipeptidyl-peptidase IV inhibitors, Obese, Predictive factors
FullTexts / Linksout information
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø